Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,144
archived clinical trials in
Ocular

Efficacy and Safety Study of MC-1101 1% TID in the Treatment of Nonexudative Age-Related Macular Degeneration
Phase II/III Study of the Efficacy and Safety of Macuclear MC-1101 1% TID in the Treatment of Nonexudative Age-Related Macular Degeneration
Status: Enrolling
Updated:  11/9/2012
University of Michigan
mi
from
Ann Arbor, MI
Efficacy and Safety Study of MC-1101 1% TID in the Treatment of Nonexudative Age-Related Macular Degeneration
Phase II/III Study of the Efficacy and Safety of Macuclear MC-1101 1% TID in the Treatment of Nonexudative Age-Related Macular Degeneration
Status: Enrolling
Updated: 11/9/2012
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
A Phase IIa Study to Assess the Tolerability, Safety, and Efficacy of AZD4017 for Raised Intra-ocular Pressure
A Double Masked, Placebo Controlled, Randomised, Parallel Group Phase IIa Study to Assess the Tolerability, Safety, and Efficacy of AZD4017 for Raised Intra-Ocular Pressure
Status: Enrolling
Updated:  11/14/2012
Clinical Research Facility
mi
from
San Diego, CA
A Phase IIa Study to Assess the Tolerability, Safety, and Efficacy of AZD4017 for Raised Intra-ocular Pressure
A Double Masked, Placebo Controlled, Randomised, Parallel Group Phase IIa Study to Assess the Tolerability, Safety, and Efficacy of AZD4017 for Raised Intra-Ocular Pressure
Status: Enrolling
Updated: 11/14/2012
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
A Phase IIa Study to Assess the Tolerability, Safety, and Efficacy of AZD4017 for Raised Intra-ocular Pressure
A Double Masked, Placebo Controlled, Randomised, Parallel Group Phase IIa Study to Assess the Tolerability, Safety, and Efficacy of AZD4017 for Raised Intra-Ocular Pressure
Status: Enrolling
Updated:  11/14/2012
Clinical Research Facility
mi
from
Atlanta, GA
A Phase IIa Study to Assess the Tolerability, Safety, and Efficacy of AZD4017 for Raised Intra-ocular Pressure
A Double Masked, Placebo Controlled, Randomised, Parallel Group Phase IIa Study to Assess the Tolerability, Safety, and Efficacy of AZD4017 for Raised Intra-Ocular Pressure
Status: Enrolling
Updated: 11/14/2012
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Phase IIa Study to Assess the Tolerability, Safety, and Efficacy of AZD4017 for Raised Intra-ocular Pressure
A Double Masked, Placebo Controlled, Randomised, Parallel Group Phase IIa Study to Assess the Tolerability, Safety, and Efficacy of AZD4017 for Raised Intra-Ocular Pressure
Status: Enrolling
Updated:  11/14/2012
Clinical Research Facility
mi
from
Kansas City, KA
A Phase IIa Study to Assess the Tolerability, Safety, and Efficacy of AZD4017 for Raised Intra-ocular Pressure
A Double Masked, Placebo Controlled, Randomised, Parallel Group Phase IIa Study to Assess the Tolerability, Safety, and Efficacy of AZD4017 for Raised Intra-Ocular Pressure
Status: Enrolling
Updated: 11/14/2012
Clinical Research Facility
mi
from
Kansas City, KA
Click here to add this to my saved trials
A Phase IIa Study to Assess the Tolerability, Safety, and Efficacy of AZD4017 for Raised Intra-ocular Pressure
A Double Masked, Placebo Controlled, Randomised, Parallel Group Phase IIa Study to Assess the Tolerability, Safety, and Efficacy of AZD4017 for Raised Intra-Ocular Pressure
Status: Enrolling
Updated:  11/14/2012
Clinical Research Facility
mi
from
Asheville, NC
A Phase IIa Study to Assess the Tolerability, Safety, and Efficacy of AZD4017 for Raised Intra-ocular Pressure
A Double Masked, Placebo Controlled, Randomised, Parallel Group Phase IIa Study to Assess the Tolerability, Safety, and Efficacy of AZD4017 for Raised Intra-Ocular Pressure
Status: Enrolling
Updated: 11/14/2012
Clinical Research Facility
mi
from
Asheville, NC
Click here to add this to my saved trials
A Phase IIa Study to Assess the Tolerability, Safety, and Efficacy of AZD4017 for Raised Intra-ocular Pressure
A Double Masked, Placebo Controlled, Randomised, Parallel Group Phase IIa Study to Assess the Tolerability, Safety, and Efficacy of AZD4017 for Raised Intra-Ocular Pressure
Status: Enrolling
Updated:  11/14/2012
Clinical Research Facility
mi
from
Allentown, PA
A Phase IIa Study to Assess the Tolerability, Safety, and Efficacy of AZD4017 for Raised Intra-ocular Pressure
A Double Masked, Placebo Controlled, Randomised, Parallel Group Phase IIa Study to Assess the Tolerability, Safety, and Efficacy of AZD4017 for Raised Intra-Ocular Pressure
Status: Enrolling
Updated: 11/14/2012
Clinical Research Facility
mi
from
Allentown, PA
Click here to add this to my saved trials
A Phase IIa Study to Assess the Tolerability, Safety, and Efficacy of AZD4017 for Raised Intra-ocular Pressure
A Double Masked, Placebo Controlled, Randomised, Parallel Group Phase IIa Study to Assess the Tolerability, Safety, and Efficacy of AZD4017 for Raised Intra-Ocular Pressure
Status: Enrolling
Updated:  11/14/2012
Clinical Research Facility
mi
from
Chattanooga, TN
A Phase IIa Study to Assess the Tolerability, Safety, and Efficacy of AZD4017 for Raised Intra-ocular Pressure
A Double Masked, Placebo Controlled, Randomised, Parallel Group Phase IIa Study to Assess the Tolerability, Safety, and Efficacy of AZD4017 for Raised Intra-Ocular Pressure
Status: Enrolling
Updated: 11/14/2012
Clinical Research Facility
mi
from
Chattanooga, TN
Click here to add this to my saved trials
A Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months
Phase 2b Dose-response of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months
Status: Enrolling
Updated:  11/15/2012
Kenneth Sall, M.D.
mi
from
Artesia, CA
A Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months
Phase 2b Dose-response of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months
Status: Enrolling
Updated: 11/15/2012
Kenneth Sall, M.D.
mi
from
Artesia, CA
Click here to add this to my saved trials
A Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months
Phase 2b Dose-response of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months
Status: Enrolling
Updated:  11/15/2012
Aesthetic Eye Care Institute
mi
from
Newport Beach, CA
A Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months
Phase 2b Dose-response of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months
Status: Enrolling
Updated: 11/15/2012
Aesthetic Eye Care Institute
mi
from
Newport Beach, CA
Click here to add this to my saved trials
A Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months
Phase 2b Dose-response of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months
Status: Enrolling
Updated:  11/15/2012
Bacharach practice
mi
from
Petaluma, CA
A Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months
Phase 2b Dose-response of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months
Status: Enrolling
Updated: 11/15/2012
Bacharach practice
mi
from
Petaluma, CA
Click here to add this to my saved trials
A Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months
Phase 2b Dose-response of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months
Status: Enrolling
Updated:  11/15/2012
Clayton Eye Center
mi
from
Morrow, GA
A Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months
Phase 2b Dose-response of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months
Status: Enrolling
Updated: 11/15/2012
Clayton Eye Center
mi
from
Morrow, GA
Click here to add this to my saved trials
A Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months
Phase 2b Dose-response of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months
Status: Enrolling
Updated:  11/15/2012
Coastal Research Associates, LLC
mi
from
Roswell, GA
A Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months
Phase 2b Dose-response of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months
Status: Enrolling
Updated: 11/15/2012
Coastal Research Associates, LLC
mi
from
Roswell, GA
Click here to add this to my saved trials
A Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months
Phase 2b Dose-response of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months
Status: Enrolling
Updated:  11/15/2012
Bradley Kwapiszeski, MD
mi
from
Shawnee Mission, KA
A Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months
Phase 2b Dose-response of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months
Status: Enrolling
Updated: 11/15/2012
Bradley Kwapiszeski, MD
mi
from
Shawnee Mission, KA
Click here to add this to my saved trials
A Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months
Phase 2b Dose-response of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months
Status: Enrolling
Updated:  11/15/2012
Taustine Eye Center
mi
from
Louisville, KY
A Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months
Phase 2b Dose-response of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months
Status: Enrolling
Updated: 11/15/2012
Taustine Eye Center
mi
from
Louisville, KY
Click here to add this to my saved trials
A Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months
Phase 2b Dose-response of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months
Status: Enrolling
Updated:  11/15/2012
Rochester Ophthalmological Group
mi
from
Rochester, NY
A Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months
Phase 2b Dose-response of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months
Status: Enrolling
Updated: 11/15/2012
Rochester Ophthalmological Group
mi
from
Rochester, NY
Click here to add this to my saved trials
A Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months
Phase 2b Dose-response of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months
Status: Enrolling
Updated:  11/15/2012
Charlotte Eye Ear Nose and Throat
mi
from
Charlotte, NC
A Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months
Phase 2b Dose-response of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months
Status: Enrolling
Updated: 11/15/2012
Charlotte Eye Ear Nose and Throat
mi
from
Charlotte, NC
Click here to add this to my saved trials
A Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months
Phase 2b Dose-response of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months
Status: Enrolling
Updated:  11/15/2012
Michael E. Tepedino, M.D.
mi
from
High Point, NC
A Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months
Phase 2b Dose-response of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months
Status: Enrolling
Updated: 11/15/2012
Michael E. Tepedino, M.D.
mi
from
High Point, NC
Click here to add this to my saved trials
A Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months
Phase 2b Dose-response of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months
Status: Enrolling
Updated:  11/15/2012
The Eye Institute
mi
from
Tulsa, OK
A Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months
Phase 2b Dose-response of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months
Status: Enrolling
Updated: 11/15/2012
The Eye Institute
mi
from
Tulsa, OK
Click here to add this to my saved trials
A Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months
Phase 2b Dose-response of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months
Status: Enrolling
Updated:  11/15/2012
Texan Eye
mi
from
Austin, TX
A Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months
Phase 2b Dose-response of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months
Status: Enrolling
Updated: 11/15/2012
Texan Eye
mi
from
Austin, TX
Click here to add this to my saved trials
A Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months
Phase 2b Dose-response of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months
Status: Enrolling
Updated:  11/15/2012
Cataract & Glaucoma Center
mi
from
El Paso, TX
A Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months
Phase 2b Dose-response of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months
Status: Enrolling
Updated: 11/15/2012
Cataract & Glaucoma Center
mi
from
El Paso, TX
Click here to add this to my saved trials
A Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months
Phase 2b Dose-response of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months
Status: Enrolling
Updated:  11/15/2012
Medical Center Ophth. Associates
mi
from
San Antonio, TX
A Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months
Phase 2b Dose-response of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months
Status: Enrolling
Updated: 11/15/2012
Medical Center Ophth. Associates
mi
from
San Antonio, TX
Click here to add this to my saved trials
Diurnal Variation in Tear Osmolarity
Investigator Sponsored, Pilot Study to Assess the Diurnal Variation in Tear Osmolarity as a Predictor of Dry Eye Disease Etiology
Status: Enrolling
Updated:  11/16/2012
Ophthalmic Consultants of Connecticut
mi
from
Fairfield, CT
Diurnal Variation in Tear Osmolarity
Investigator Sponsored, Pilot Study to Assess the Diurnal Variation in Tear Osmolarity as a Predictor of Dry Eye Disease Etiology
Status: Enrolling
Updated: 11/16/2012
Ophthalmic Consultants of Connecticut
mi
from
Fairfield, CT
Click here to add this to my saved trials
Diurnal Variation in Tear Osmolarity
Investigator Sponsored, Pilot Study to Assess the Diurnal Variation in Tear Osmolarity as a Predictor of Dry Eye Disease Etiology
Status: Enrolling
Updated:  11/16/2012
Ophthalmic Consultants of Long Island
mi
from
Lynbrook, NY
Diurnal Variation in Tear Osmolarity
Investigator Sponsored, Pilot Study to Assess the Diurnal Variation in Tear Osmolarity as a Predictor of Dry Eye Disease Etiology
Status: Enrolling
Updated: 11/16/2012
Ophthalmic Consultants of Long Island
mi
from
Lynbrook, NY
Click here to add this to my saved trials
Diurnal Variation in Tear Osmolarity
Investigator Sponsored, Pilot Study to Assess the Diurnal Variation in Tear Osmolarity as a Predictor of Dry Eye Disease Etiology
Status: Enrolling
Updated:  11/16/2012
Ophthalmic Consultants of Long Island
mi
from
Manhasset, NY
Diurnal Variation in Tear Osmolarity
Investigator Sponsored, Pilot Study to Assess the Diurnal Variation in Tear Osmolarity as a Predictor of Dry Eye Disease Etiology
Status: Enrolling
Updated: 11/16/2012
Ophthalmic Consultants of Long Island
mi
from
Manhasset, NY
Click here to add this to my saved trials
Diurnal Variation in Tear Osmolarity
Investigator Sponsored, Pilot Study to Assess the Diurnal Variation in Tear Osmolarity as a Predictor of Dry Eye Disease Etiology
Status: Enrolling
Updated:  11/16/2012
Ophthalmic Consultants of Long Island
mi
from
Port Jefferson, NY
Diurnal Variation in Tear Osmolarity
Investigator Sponsored, Pilot Study to Assess the Diurnal Variation in Tear Osmolarity as a Predictor of Dry Eye Disease Etiology
Status: Enrolling
Updated: 11/16/2012
Ophthalmic Consultants of Long Island
mi
from
Port Jefferson, NY
Click here to add this to my saved trials
Diurnal Variation in Tear Osmolarity
Investigator Sponsored, Pilot Study to Assess the Diurnal Variation in Tear Osmolarity as a Predictor of Dry Eye Disease Etiology
Status: Enrolling
Updated:  11/16/2012
Ophthalmic Consultants of Long Island
mi
from
Rockville Centre, NY
Diurnal Variation in Tear Osmolarity
Investigator Sponsored, Pilot Study to Assess the Diurnal Variation in Tear Osmolarity as a Predictor of Dry Eye Disease Etiology
Status: Enrolling
Updated: 11/16/2012
Ophthalmic Consultants of Long Island
mi
from
Rockville Centre, NY
Click here to add this to my saved trials
Diurnal Variation in Tear Osmolarity
Investigator Sponsored, Pilot Study to Assess the Diurnal Variation in Tear Osmolarity as a Predictor of Dry Eye Disease Etiology
Status: Enrolling
Updated:  11/16/2012
Ophthalmic Consultants of Long Island
mi
from
Valley Stream, NY
Diurnal Variation in Tear Osmolarity
Investigator Sponsored, Pilot Study to Assess the Diurnal Variation in Tear Osmolarity as a Predictor of Dry Eye Disease Etiology
Status: Enrolling
Updated: 11/16/2012
Ophthalmic Consultants of Long Island
mi
from
Valley Stream, NY
Click here to add this to my saved trials
Corneal Sensation and Incidence of Dry Eye Post Refractive Cataract Extraction With FemtoSecond Laser
A Post Market Pilot Study To Evaluate Corneal Sensation And The Incidence Of Dry Eye In Subjects Undergoing Refractive Cataract Extraction With The Femtosecond Laser For Arcuate Relaxing Incisions
Status: Enrolling
Updated:  11/16/2012
Ophthlamic Consultants of Long Island - Rockville Centre
mi
from
Rockville Centre, NY
Corneal Sensation and Incidence of Dry Eye Post Refractive Cataract Extraction With FemtoSecond Laser
A Post Market Pilot Study To Evaluate Corneal Sensation And The Incidence Of Dry Eye In Subjects Undergoing Refractive Cataract Extraction With The Femtosecond Laser For Arcuate Relaxing Incisions
Status: Enrolling
Updated: 11/16/2012
Ophthlamic Consultants of Long Island - Rockville Centre
mi
from
Rockville Centre, NY
Click here to add this to my saved trials
Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle Glaucoma
A Phase 2a, Randomized, Double-masked, Placebo-controlled, Dose-escalation Study of AMA0076 in Topical Ocular Formulation for Safety, Tolerability and Efficacy in Reduction of Intraocular Pressure in Subjects With Ocular Hypertension or Primary Open-angle Glaucoma
Status: Enrolling
Updated:  11/23/2012
Artesia Clinical Site - Site 02
mi
from
Artesia, CA
Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle Glaucoma
A Phase 2a, Randomized, Double-masked, Placebo-controlled, Dose-escalation Study of AMA0076 in Topical Ocular Formulation for Safety, Tolerability and Efficacy in Reduction of Intraocular Pressure in Subjects With Ocular Hypertension or Primary Open-angle Glaucoma
Status: Enrolling
Updated: 11/23/2012
Artesia Clinical Site - Site 02
mi
from
Artesia, CA
Click here to add this to my saved trials
Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle Glaucoma
A Phase 2a, Randomized, Double-masked, Placebo-controlled, Dose-escalation Study of AMA0076 in Topical Ocular Formulation for Safety, Tolerability and Efficacy in Reduction of Intraocular Pressure in Subjects With Ocular Hypertension or Primary Open-angle Glaucoma
Status: Enrolling
Updated:  11/23/2012
Inglewood Clinical Site - Site 03
mi
from
Inglewood, CA
Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle Glaucoma
A Phase 2a, Randomized, Double-masked, Placebo-controlled, Dose-escalation Study of AMA0076 in Topical Ocular Formulation for Safety, Tolerability and Efficacy in Reduction of Intraocular Pressure in Subjects With Ocular Hypertension or Primary Open-angle Glaucoma
Status: Enrolling
Updated: 11/23/2012
Inglewood Clinical Site - Site 03
mi
from
Inglewood, CA
Click here to add this to my saved trials
Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle Glaucoma
A Phase 2a, Randomized, Double-masked, Placebo-controlled, Dose-escalation Study of AMA0076 in Topical Ocular Formulation for Safety, Tolerability and Efficacy in Reduction of Intraocular Pressure in Subjects With Ocular Hypertension or Primary Open-angle Glaucoma
Status: Enrolling
Updated:  11/23/2012
Petaluma Clinical Site - Site 05
mi
from
Petaluma, CA
Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle Glaucoma
A Phase 2a, Randomized, Double-masked, Placebo-controlled, Dose-escalation Study of AMA0076 in Topical Ocular Formulation for Safety, Tolerability and Efficacy in Reduction of Intraocular Pressure in Subjects With Ocular Hypertension or Primary Open-angle Glaucoma
Status: Enrolling
Updated: 11/23/2012
Petaluma Clinical Site - Site 05
mi
from
Petaluma, CA
Click here to add this to my saved trials
Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle Glaucoma
A Phase 2a, Randomized, Double-masked, Placebo-controlled, Dose-escalation Study of AMA0076 in Topical Ocular Formulation for Safety, Tolerability and Efficacy in Reduction of Intraocular Pressure in Subjects With Ocular Hypertension or Primary Open-angle Glaucoma
Status: Enrolling
Updated:  11/23/2012
New Haven Clinical Site - Site 01
mi
from
New Haven, CT
Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle Glaucoma
A Phase 2a, Randomized, Double-masked, Placebo-controlled, Dose-escalation Study of AMA0076 in Topical Ocular Formulation for Safety, Tolerability and Efficacy in Reduction of Intraocular Pressure in Subjects With Ocular Hypertension or Primary Open-angle Glaucoma
Status: Enrolling
Updated: 11/23/2012
New Haven Clinical Site - Site 01
mi
from
New Haven, CT
Click here to add this to my saved trials
Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle Glaucoma
A Phase 2a, Randomized, Double-masked, Placebo-controlled, Dose-escalation Study of AMA0076 in Topical Ocular Formulation for Safety, Tolerability and Efficacy in Reduction of Intraocular Pressure in Subjects With Ocular Hypertension or Primary Open-angle Glaucoma
Status: Enrolling
Updated:  11/23/2012
Atlanta Clinical Site - Site 04
mi
from
Atlanta, GA
Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle Glaucoma
A Phase 2a, Randomized, Double-masked, Placebo-controlled, Dose-escalation Study of AMA0076 in Topical Ocular Formulation for Safety, Tolerability and Efficacy in Reduction of Intraocular Pressure in Subjects With Ocular Hypertension or Primary Open-angle Glaucoma
Status: Enrolling
Updated: 11/23/2012
Atlanta Clinical Site - Site 04
mi
from
Atlanta, GA
Click here to add this to my saved trials
Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle Glaucoma
A Phase 2a, Randomized, Double-masked, Placebo-controlled, Dose-escalation Study of AMA0076 in Topical Ocular Formulation for Safety, Tolerability and Efficacy in Reduction of Intraocular Pressure in Subjects With Ocular Hypertension or Primary Open-angle Glaucoma
Status: Enrolling
Updated:  11/23/2012
High Point Clinical Site - Site 06
mi
from
High Point, NC
Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle Glaucoma
A Phase 2a, Randomized, Double-masked, Placebo-controlled, Dose-escalation Study of AMA0076 in Topical Ocular Formulation for Safety, Tolerability and Efficacy in Reduction of Intraocular Pressure in Subjects With Ocular Hypertension or Primary Open-angle Glaucoma
Status: Enrolling
Updated: 11/23/2012
High Point Clinical Site - Site 06
mi
from
High Point, NC
Click here to add this to my saved trials
A Safety, Tolerability and Pharmacokinetics Study of R932348 Eye Drops in Patients With Dry Eye Disease
A Phase 1, Single Center, Randomized, Double-Blind, Placebo-Controlled, Ascending Dose, Pharmacokinetics, Tolerability and Safety Study of R932348 Ophthalmic Solution in Patients With Mild to Moderate Keratoconjunctivitis Sicca
Status: Enrolling
Updated:  11/29/2012
Andover Eye Associates
mi
from
Andover, MA
A Safety, Tolerability and Pharmacokinetics Study of R932348 Eye Drops in Patients With Dry Eye Disease
A Phase 1, Single Center, Randomized, Double-Blind, Placebo-Controlled, Ascending Dose, Pharmacokinetics, Tolerability and Safety Study of R932348 Ophthalmic Solution in Patients With Mild to Moderate Keratoconjunctivitis Sicca
Status: Enrolling
Updated: 11/29/2012
Andover Eye Associates
mi
from
Andover, MA
Click here to add this to my saved trials
A Multi-Center Study Subjects With Dry Eye Syndrome
A Multi-Center, Double Masked, Randomized, Placebo-Controlled, Dose-Ranging Study of EBI-005 Ophthalmic Solution Versus Placebo in Subjects With Dry Eye Syndrome
Status: Enrolling
Updated:  12/7/2012
Sall Research Medical Center, Inc.
mi
from
Artesia, CA
A Multi-Center Study Subjects With Dry Eye Syndrome
A Multi-Center, Double Masked, Randomized, Placebo-Controlled, Dose-Ranging Study of EBI-005 Ophthalmic Solution Versus Placebo in Subjects With Dry Eye Syndrome
Status: Enrolling
Updated: 12/7/2012
Sall Research Medical Center, Inc.
mi
from
Artesia, CA
Click here to add this to my saved trials
A Multi-Center Study Subjects With Dry Eye Syndrome
A Multi-Center, Double Masked, Randomized, Placebo-Controlled, Dose-Ranging Study of EBI-005 Ophthalmic Solution Versus Placebo in Subjects With Dry Eye Syndrome
Status: Enrolling
Updated:  12/7/2012
Martel Eye Medical Group
mi
from
Rancho Cordova, CA
A Multi-Center Study Subjects With Dry Eye Syndrome
A Multi-Center, Double Masked, Randomized, Placebo-Controlled, Dose-Ranging Study of EBI-005 Ophthalmic Solution Versus Placebo in Subjects With Dry Eye Syndrome
Status: Enrolling
Updated: 12/7/2012
Martel Eye Medical Group
mi
from
Rancho Cordova, CA
Click here to add this to my saved trials
A Multi-Center Study Subjects With Dry Eye Syndrome
A Multi-Center, Double Masked, Randomized, Placebo-Controlled, Dose-Ranging Study of EBI-005 Ophthalmic Solution Versus Placebo in Subjects With Dry Eye Syndrome
Status: Enrolling
Updated:  12/7/2012
Wolstan & Goldberg Eye Associates
mi
from
Torrence, CA
A Multi-Center Study Subjects With Dry Eye Syndrome
A Multi-Center, Double Masked, Randomized, Placebo-Controlled, Dose-Ranging Study of EBI-005 Ophthalmic Solution Versus Placebo in Subjects With Dry Eye Syndrome
Status: Enrolling
Updated: 12/7/2012
Wolstan & Goldberg Eye Associates
mi
from
Torrence, CA
Click here to add this to my saved trials
A Multi-Center Study Subjects With Dry Eye Syndrome
A Multi-Center, Double Masked, Randomized, Placebo-Controlled, Dose-Ranging Study of EBI-005 Ophthalmic Solution Versus Placebo in Subjects With Dry Eye Syndrome
Status: Enrolling
Updated:  12/7/2012
Eye Clinics of South Texas
mi
from
San Antonio, TX
A Multi-Center Study Subjects With Dry Eye Syndrome
A Multi-Center, Double Masked, Randomized, Placebo-Controlled, Dose-Ranging Study of EBI-005 Ophthalmic Solution Versus Placebo in Subjects With Dry Eye Syndrome
Status: Enrolling
Updated: 12/7/2012
Eye Clinics of South Texas
mi
from
San Antonio, TX
Click here to add this to my saved trials
Safety and Efficacy Trial to Treat Open-Angle Glaucoma or Ocular Hypertension
A Phase I/II Dose Escalation Safety and Efficacy Trial of DE-112 Ophthalmic Solution in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension
Status: Enrolling
Updated:  12/14/2012
Clinical Research Facility
mi
from
Austin, TX
Safety and Efficacy Trial to Treat Open-Angle Glaucoma or Ocular Hypertension
A Phase I/II Dose Escalation Safety and Efficacy Trial of DE-112 Ophthalmic Solution in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension
Status: Enrolling
Updated: 12/14/2012
Clinical Research Facility
mi
from
Austin, TX
Click here to add this to my saved trials
Safety and Efficacy Trial to Treat Open-Angle Glaucoma or Ocular Hypertension
A Phase I/II Dose Escalation Safety and Efficacy Trial of DE-112 Ophthalmic Solution in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension
Status: Enrolling
Updated:  12/14/2012
Clinical Research Facility
mi
from
San Antonio, TX
Safety and Efficacy Trial to Treat Open-Angle Glaucoma or Ocular Hypertension
A Phase I/II Dose Escalation Safety and Efficacy Trial of DE-112 Ophthalmic Solution in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension
Status: Enrolling
Updated: 12/14/2012
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients
A Phase II Prospective, Randomized, Double-Masked, Parallel-Group, Multi-centered Study Assessing the Safety and Efficacy of Two Concentrations of DE-101 Ophthalmic Suspension Compared to Placebo for the Treatment of Dry Eye Disease
Status: Enrolling
Updated:  12/14/2012
mi
from
New Port Beach, CA
A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients
A Phase II Prospective, Randomized, Double-Masked, Parallel-Group, Multi-centered Study Assessing the Safety and Efficacy of Two Concentrations of DE-101 Ophthalmic Suspension Compared to Placebo for the Treatment of Dry Eye Disease
Status: Enrolling
Updated: 12/14/2012
mi
from
New Port Beach, CA
Click here to add this to my saved trials
A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients
A Phase II Prospective, Randomized, Double-Masked, Parallel-Group, Multi-centered Study Assessing the Safety and Efficacy of Two Concentrations of DE-101 Ophthalmic Suspension Compared to Placebo for the Treatment of Dry Eye Disease
Status: Enrolling
Updated:  12/14/2012
Clinical Research Facility
mi
from
Parker, CO
A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients
A Phase II Prospective, Randomized, Double-Masked, Parallel-Group, Multi-centered Study Assessing the Safety and Efficacy of Two Concentrations of DE-101 Ophthalmic Suspension Compared to Placebo for the Treatment of Dry Eye Disease
Status: Enrolling
Updated: 12/14/2012
Clinical Research Facility
mi
from
Parker, CO
Click here to add this to my saved trials
A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients
A Phase II Prospective, Randomized, Double-Masked, Parallel-Group, Multi-centered Study Assessing the Safety and Efficacy of Two Concentrations of DE-101 Ophthalmic Suspension Compared to Placebo for the Treatment of Dry Eye Disease
Status: Enrolling
Updated:  12/14/2012
Clinical Research Facility
mi
from
Largo, FL
A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients
A Phase II Prospective, Randomized, Double-Masked, Parallel-Group, Multi-centered Study Assessing the Safety and Efficacy of Two Concentrations of DE-101 Ophthalmic Suspension Compared to Placebo for the Treatment of Dry Eye Disease
Status: Enrolling
Updated: 12/14/2012
Clinical Research Facility
mi
from
Largo, FL
Click here to add this to my saved trials
A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients
A Phase II Prospective, Randomized, Double-Masked, Parallel-Group, Multi-centered Study Assessing the Safety and Efficacy of Two Concentrations of DE-101 Ophthalmic Suspension Compared to Placebo for the Treatment of Dry Eye Disease
Status: Enrolling
Updated:  12/14/2012
Clinical Research Facility
mi
from
Morrow, GA
A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients
A Phase II Prospective, Randomized, Double-Masked, Parallel-Group, Multi-centered Study Assessing the Safety and Efficacy of Two Concentrations of DE-101 Ophthalmic Suspension Compared to Placebo for the Treatment of Dry Eye Disease
Status: Enrolling
Updated: 12/14/2012
Clinical Research Facility
mi
from
Morrow, GA
Click here to add this to my saved trials
A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients
A Phase II Prospective, Randomized, Double-Masked, Parallel-Group, Multi-centered Study Assessing the Safety and Efficacy of Two Concentrations of DE-101 Ophthalmic Suspension Compared to Placebo for the Treatment of Dry Eye Disease
Status: Enrolling
Updated:  12/14/2012
Clinical Research Facility
mi
from
Roswell, GA
A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients
A Phase II Prospective, Randomized, Double-Masked, Parallel-Group, Multi-centered Study Assessing the Safety and Efficacy of Two Concentrations of DE-101 Ophthalmic Suspension Compared to Placebo for the Treatment of Dry Eye Disease
Status: Enrolling
Updated: 12/14/2012
Clinical Research Facility
mi
from
Roswell, GA
Click here to add this to my saved trials
A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients
A Phase II Prospective, Randomized, Double-Masked, Parallel-Group, Multi-centered Study Assessing the Safety and Efficacy of Two Concentrations of DE-101 Ophthalmic Suspension Compared to Placebo for the Treatment of Dry Eye Disease
Status: Enrolling
Updated:  12/14/2012
Clinical Research Facility
mi
from
Bangor, ME
A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients
A Phase II Prospective, Randomized, Double-Masked, Parallel-Group, Multi-centered Study Assessing the Safety and Efficacy of Two Concentrations of DE-101 Ophthalmic Suspension Compared to Placebo for the Treatment of Dry Eye Disease
Status: Enrolling
Updated: 12/14/2012
Clinical Research Facility
mi
from
Bangor, ME
Click here to add this to my saved trials
A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients
A Phase II Prospective, Randomized, Double-Masked, Parallel-Group, Multi-centered Study Assessing the Safety and Efficacy of Two Concentrations of DE-101 Ophthalmic Suspension Compared to Placebo for the Treatment of Dry Eye Disease
Status: Enrolling
Updated:  12/14/2012
Clinical Research Facility
mi
from
Kansas City, MO
A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients
A Phase II Prospective, Randomized, Double-Masked, Parallel-Group, Multi-centered Study Assessing the Safety and Efficacy of Two Concentrations of DE-101 Ophthalmic Suspension Compared to Placebo for the Treatment of Dry Eye Disease
Status: Enrolling
Updated: 12/14/2012
Clinical Research Facility
mi
from
Kansas City, MO
Click here to add this to my saved trials
A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients
A Phase II Prospective, Randomized, Double-Masked, Parallel-Group, Multi-centered Study Assessing the Safety and Efficacy of Two Concentrations of DE-101 Ophthalmic Suspension Compared to Placebo for the Treatment of Dry Eye Disease
Status: Enrolling
Updated:  12/14/2012
Clinical Research Facility
mi
from
Saint Louis, MO
A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients
A Phase II Prospective, Randomized, Double-Masked, Parallel-Group, Multi-centered Study Assessing the Safety and Efficacy of Two Concentrations of DE-101 Ophthalmic Suspension Compared to Placebo for the Treatment of Dry Eye Disease
Status: Enrolling
Updated: 12/14/2012
Clinical Research Facility
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients
A Phase II Prospective, Randomized, Double-Masked, Parallel-Group, Multi-centered Study Assessing the Safety and Efficacy of Two Concentrations of DE-101 Ophthalmic Suspension Compared to Placebo for the Treatment of Dry Eye Disease
Status: Enrolling
Updated:  12/14/2012
Clinical Research Facility
mi
from
Washington, MO
A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients
A Phase II Prospective, Randomized, Double-Masked, Parallel-Group, Multi-centered Study Assessing the Safety and Efficacy of Two Concentrations of DE-101 Ophthalmic Suspension Compared to Placebo for the Treatment of Dry Eye Disease
Status: Enrolling
Updated: 12/14/2012
Clinical Research Facility
mi
from
Washington, MO
Click here to add this to my saved trials